Neurology News and Research

Latest Neurology News and Research

Measuring children's blood pressure is complicated: Researchers

A Johns Hopkins Children's Center study of 2,500 patient records suggests that medical staff fails to check a child's blood pressure a fifth of the time, and is not recognizing what constitutes an abnormal reading in those whose blood pressure they do check.

3 May 2010

New tool may help neurologists predict candidates for organ donation

A new tool may help neurologists predict which coma patients may be candidates for organ donation, according to a study published in the April 27, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

3 May 2010

Neuralstem's stem cell treatment for ALS featured on CNN with Dr. Sanjay Gupta

Neuralstem, Inc. announced that its stem cell treatment for ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease), currently in a FDA-approved Phase I clinical trial, was featured on CNN last night with Dr. Sanjay Gupta, in the piece entitled "Stem Cell Medical Breakthrough".

30 Apr 2010

Endo Pharmaceuticals reports 9% increase in first-quarter 2010 revenues

Endo Pharmaceuticals today reported financial results for the first quarter 2010.

30 Apr 2010

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

Acorda Therapeutics, Inc. today announced its financial results for the first quarter of 2010.

30 Apr 2010

Nationwide Children's Hospital opens first pediatric Pseudotumor Cerebri Clinic in the U.S.

While most headaches in children can be treated with over-the-counter pain medications or lifestyle changes, it is important to pay attention to their symptoms in case they herald something more serious.

30 Apr 2010

Low vitamin D levels may be associated with physical disability, cognitive impairment in MS patients

Low vitamin D levels may be associated with more advanced physical disability and cognitive impairment in persons with multiple sclerosis, studies conducted by neurologists at the University at Buffalo have shown.

30 Apr 2010

Continuing education lectures on adult glioblastoma to be held at all U.S. healthcare centers

Adult glioblastoma continues to be a difficult disease to treat, so healthcare professionals must have the most up-to-date information regarding optimal methods for diagnostic imaging and treatment of these tumors. Awareness of novel agents in clinical trials is also critical to providing the best care.

30 Apr 2010

Natus Medical's revenue for first-quarter 2010 increased 47% to $49.2M

Natus Medical Incorporated today announced financial results for the three months ended March 31, 2010.

29 Apr 2010

Power3 Medical Products to present four abstracts at International Congress of Alzheimer's Disease

Power3 Medical Products, Inc. announced that four abstracts were accepted for presentation to the annual meeting of the International Congress of Alzheimer's Disease on July 12, 2010 in Honolulu, Hawaii. The presentations will cover results from protein biomarker discovery, drug response, test development, and ongoing clinical validation trials of the NuroPro AD biomarkers and blood test for Alzheimer's disease.

29 Apr 2010

Removing unruptured AVM decreases risk of hemorrhaging, provides better outcomes to patients

Individuals diagnosed with a brain arteriovenous malformation, an abnormal tangle of arteries and veins, are at an increased risk of vessel rupture and bleeding that can cause stroke and permanent brain damage.

29 Apr 2010

Panel finds insufficient evidence to support preventive measures for cognitive decline, Alzheimer's disease

Many preventive measures for cognitive decline and for preventing Alzheimer's disease-mental stimulation, exercise, and a variety of dietary supplements-have been studied over the years. However, an independent panel convened this week by the National Institutes of Health determined that the value of these strategies for delaying the onset and/or reducing the severity of decline or disease hasn't been demonstrated in rigorous studies.

29 Apr 2010

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Ipsen, a global biopharmaceutical group, today announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence. Taspoglutide originating from Ipsen's research is developed by Roche.

29 Apr 2010

Talecris Biotherapeutics first-quarter net income increases 35.6% to $45.3 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three months ended March 31, 2010, and filed its first quarter 2010 Form 10-Q with the U.S. Securities and Exchange Commission (SEC).

29 Apr 2010

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.

28 Apr 2010

Researchers find Alzheimer's pathology to originate from Amyloid-Beta oligomers in the brain

Using a new mouse model of Alzheimer's disease, researchers at Mount Sinai School of Medicine have found that Alzheimer's pathology originates in Amyloid-Beta (Abeta) oligomers in the brain, rather than the amyloid plaques previously thought by many researchers to cause the disease.

28 Apr 2010

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB) under investigation for the treatment of hypertension. Discovered by Takeda, azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II.

28 Apr 2010

Natus Medical announces $50M revolving credit facility with Wells Fargo Bank

Natus Medical Incorporated today announced that it has entered into a $50 million revolving credit facility with Wells Fargo Bank, National Association. The credit facility, which matures on April 30, 2012, amends and restates the Company's existing $25 million credit facility that was scheduled to mature on April 30, 2010.

27 Apr 2010

Slitrk5 gene linked to development of OCD-like behaviors

Researchers at the Ansary Stem Cell Institute and the Department of Psychiatry at Weill Cornell Medical College discovered that mice missing a single gene developed repetitive obsessive-compulsive-like behaviors. The genetically altered mice, which behaved much like people with a certain type of obsessive-compulsive disorder (OCD), could help scientists design new therapies for this debilitating condition.

27 Apr 2010

New discovery links Slitrk5 gene to development of OCD-like behaviors

27 Apr 2010

Neurology News and Research

Latest Neurology News and Research

Measuring children's blood pressure is complicated: Researchers

New tool may help neurologists predict candidates for organ donation

Neuralstem's stem cell treatment for ALS featured on CNN with Dr. Sanjay Gupta

Endo Pharmaceuticals reports 9% increase in first-quarter 2010 revenues

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

Nationwide Children's Hospital opens first pediatric Pseudotumor Cerebri Clinic in the U.S.

Low vitamin D levels may be associated with physical disability, cognitive impairment in MS patients

Continuing education lectures on adult glioblastoma to be held at all U.S. healthcare centers

Natus Medical's revenue for first-quarter 2010 increased 47% to $49.2M

Power3 Medical Products to present four abstracts at International Congress of Alzheimer's Disease

Removing unruptured AVM decreases risk of hemorrhaging, provides better outcomes to patients

Panel finds insufficient evidence to support preventive measures for cognitive decline, Alzheimer's disease

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Talecris Biotherapeutics first-quarter net income increases 35.6% to $45.3 million

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Researchers find Alzheimer's pathology to originate from Amyloid-Beta oligomers in the brain

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Natus Medical announces $50M revolving credit facility with Wells Fargo Bank

Slitrk5 gene linked to development of OCD-like behaviors

New discovery links Slitrk5 gene to development of OCD-like behaviors

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Neurology News and Research

Latest Neurology News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in